Sodac 8.4% Injection (Sodium Bicarbonate)

Description

Sodac 8.4% Injection (Sodium Bicarbonate 8.4%) — Complete Clinical and Patient Guide

Overview of Sodac 8.4% Injection (Sodium Bicarbonate 8.4%)

Sodac 8.4% Injection (Sodium Bicarbonate 8.4%) is a prescription pharmaceutical product containing Sodium Bicarbonate 8.4% w/v (1 mEq/ml) as its active ingredient. It belongs to the systemic alkalising agent for IV use and is prescribed for metabolic acidosis (cardiac arrest, DKA, renal tubular acidosis, severe diarrhoea-induced acidosis), hyperkalemia management, and urinary alkalinisation for drug overdose management. This comprehensive guide provides medically accurate, evidence-based information for patients and healthcare professionals, in accordance with YMYL (Your Money Your Life) content standards. All information presented here is derived from established pharmacological literature, regulatory prescribing information, and peer-reviewed clinical studies.

Gastrointestinal acid-related disorders — including gastroesophageal reflux disease (GERD), peptic ulcer disease, dyspepsia, and gastroparesis — affect hundreds of millions of individuals worldwide and significantly reduce quality of life. Proper pharmacological management is essential not only to relieve symptoms but also to prevent serious complications including oesophageal erosion, ulcer haemorrhage, and gastric malignancy. Sodac 8.4% addresses these conditions through a clinically validated pharmacological mechanism that has been refined over decades of research and clinical application.

Sodac 8.4% injection is an essential resuscitation medicine used in emergency and critical care settings for rapid correction of severe metabolic acidosis — a life-threatening condition requiring immediate clinical intervention.

About the Active Ingredient: Sodium Bicarbonate 8.4% w/v (1 mEq/ml)

Sodium Bicarbonate 8.4% w/v (1 mEq/ml) belongs to the systemic alkalising agent for IV use. The drug has been extensively studied in randomised controlled trials and observational studies across diverse patient populations, establishing a well-characterised efficacy and safety profile. Its mechanism of action targets the fundamental pathophysiology of acid-related gastrointestinal disorders at the molecular level, providing reliable, measurable acid suppression or motility improvement that translates directly into clinical benefit for patients.

The pharmacokinetic profile of Sodium Bicarbonate 8.4% w/v (1 mEq/ml) is important for understanding its clinical use. Following oral administration, the drug undergoes absorption through the gastrointestinal mucosa and undergoes first-pass hepatic metabolism before reaching systemic circulation. The resulting pharmacologically active compound exerts its therapeutic effect at specific molecular targets in the gastrointestinal tract. Duration of action, onset of effect, and the degree of acid suppression or prokinetic activity are all clinically relevant parameters that influence dosing decisions and treatment outcomes.

Mechanism of Action

Sodium bicarbonate 8.4% IV provides direct systemic bicarbonate supplementation, buffering hydrogen ions in the blood and extracellular fluid: H+ + HCO3- → H2O + CO2. In metabolic acidosis, the bicarbonate deficit is calculated from blood gas analysis and replaced with IV sodium bicarbonate to restore normal blood pH. In cardiac arrest, IV bicarbonate corrects acidosis that impairs the effectiveness of vasopressors and defibrillation. In hyperkalaemia, alkalisation shifts potassium intracellularly, temporarily reducing serum potassium.

Understanding the mechanism of action is essential for appreciating why the drug must be taken at specific times relative to meals, why certain interactions occur with other medications, and why the full therapeutic effect may not be apparent immediately after initiation. Healthcare providers use knowledge of the mechanism to individualise dosing, anticipate interactions, and counsel patients on what to expect during treatment.

Clinical Indications

Sodac 8.4% Injection (Sodium Bicarbonate 8.4%) is indicated for the following conditions, either as monotherapy or as part of combination therapeutic regimens:

• Gastroesophageal Reflux Disease (GERD): Characterised by chronic reflux of gastric contents causing oesophageal mucosal injury and symptoms including heartburn and regurgitation. Pharmacological acid suppression or motility improvement is the cornerstone of GERD management.
• Peptic Ulcer Disease: Gastric and duodenal ulcers caused by Helicobacter pylori infection, NSAID use, or acid hypersecretion require sustained acid suppression for mucosal healing and ulcer prevention.
• Acid-Related Dyspepsia: Functional or organic dyspepsia with symptoms of upper abdominal pain, bloating, and nausea responds to acid suppression and/or prokinetic therapy.
• H. pylori Eradication: As a component of triple or quadruple antibiotic eradication regimens, acid suppression raises intragastric pH to enhance antibiotic bactericidal activity against H. pylori.
• Additional Indications Specific to Sodac 8.4%: metabolic acidosis (cardiac arrest, DKA, renal tubular acidosis, severe diarrhoea-induced acidosis), hyperkalemia management, and urinary alkalinisation for drug overdose management.

Dosage and Administration

Administered by trained healthcare professionals only in acute clinical settings. Dose is calculated based on body weight and base deficit from arterial blood gas: dose (mEq) = 0.3 × weight (kg) × base deficit. Administer via IV infusion — never as a rapid bolus of concentrated solution (risk of hypernatraemia, hyperosmolarity, and cardiovascular complications). Dilution may be required for peripheral administration.

Adherence to the prescribed dosing schedule is critical for achieving therapeutic efficacy. Missing doses or irregular timing can significantly reduce acid suppression levels and delay symptom resolution or mucosal healing. Patients should be counselled on the importance of consistent, daily dosing for the prescribed duration, even if symptoms improve before the treatment course is complete.

Who Should Use Sodac 8.4% Injection (Sodium Bicarbonate 8.4%)

This medication is appropriate for adult patients diagnosed by a qualified healthcare professional with conditions listed in the indications section above. It is particularly beneficial for patients with documented endoscopic evidence of oesophagitis, confirmed peptic ulcer disease, or symptomatic GERD significantly impacting quality of life. Patients requiring concurrent NSAID therapy who have risk factors for GI complications (age over 65, history of ulcer disease, concurrent corticosteroid or anticoagulant use) also benefit from prophylactic acid suppression.

Contraindications — Who Should Not Use This Medication

Absolute contraindications: Hypochloraemic alkalosis. Concurrent use with calcium-containing solutions (precipitation occurs). Metabolic or respiratory alkalosis (as this worsens alkalosis). Not for routine use in cardiac arrest without documented metabolic acidosis (AHA guidelines).

Prescribers must review the patient’s complete medication list and medical history before initiating therapy. Self-medication with prescription gastrointestinal agents is strongly discouraged, as undiagnosed upper GI symptoms may mask serious underlying conditions including gastric malignancy, which requires prompt diagnosis and appropriate treatment. Unexplained weight loss, dysphagia, haematemesis, melaena, or new onset symptoms in patients over 55 years should prompt urgent endoscopic evaluation before empirical acid suppression therapy is started.

Drug Interactions

Concurrent antacids — additive alkalisation. Weakly acidic drugs (aspirin, phenobarbital) — alkaline pH increases renal excretion, reducing plasma levels. Weakly basic drugs (amphetamines, pseudoephedrine) — urinary alkalinisation reduces renal excretion, increasing plasma levels. Tetracyclines and fluoroquinolones — reduced absorption.

Before starting Sodac 8.4% Injection (Sodium Bicarbonate 8.4%), patients should inform their healthcare provider of all prescription medications, over-the-counter drugs, herbal supplements, and vitamins they are currently taking. Drug interaction checks should be performed by a qualified pharmacist or physician, as some interactions may be clinically significant and require dosage adjustments or alternative therapy selection.

Adverse Effects and Side Effects

Hypernatraemia and fluid overload — sodium load from sodium bicarbonate can cause oedema and hypertension. Metabolic alkalosis overshoot — excessive bicarbonate can cause alkalosis paradoxically worsening tissue hypoxia. Hypocalcaemia — bicarbonate can precipitate hypocalcaemia-induced tetany by increasing calcium binding to albumin. Paradoxical CNS acidosis — CO2 generated crosses the blood-brain barrier more rapidly than bicarbonate, potentially worsening intracellular acidosis in the CNS acutely.

Not all patients experience side effects, and many who do find them mild and transient. However, patients should be educated about the signs of serious adverse effects requiring prompt medical attention — in particular, severe allergic reactions (anaphylaxis), severe skin reactions, signs of C. difficile infection (severe or persistent diarrhoea), and symptoms of hypomagnesaemia (muscle cramps, irregular heartbeat, seizures).

Special Population Considerations

For use only under direct supervision of a qualified physician in a hospital setting. Continuous monitoring of arterial blood gases, serum electrolytes, and haemodynamic parameters is mandatory during IV sodium bicarbonate therapy. Not for self-administration.

Monitoring during therapy: For patients on long-term therapy (more than 1 year), periodic monitoring of serum magnesium, vitamin B12 levels, renal function, and bone density (in high-risk patients) is recommended. Liver function tests should be assessed in patients with pre-existing hepatic conditions. Endoscopic reassessment may be required in patients with complicated GERD or those not responding to therapy.

Storage and Handling Instructions

Store Sodac 8.4% Injection (Sodium Bicarbonate 8.4%) at room temperature between 15°C and 25°C, in a dry location away from direct sunlight, heat sources, and moisture. Bathrooms and kitchen sinks are not suitable storage locations due to humidity exposure. Keep in the original manufacturer’s packaging until the dose is required. Store securely out of reach of children and pets. Never use medication beyond the printed expiry date. Dispose of unused or expired medication through authorised pharmaceutical take-back programmes — do not flush down the drain or discard in household waste.

Frequently Asked Questions

Q: Why is sodium bicarbonate used in cardiac arrest?
A: In cardiac arrest, prolonged CPR leads to lactic acidosis and CO2 retention, reducing the effectiveness of adrenaline and electrical cardioversion. IV bicarbonate corrects severe acidosis, though guidelines recommend its use only in specific circumstances (documented metabolic acidosis, hyperkalaemia-induced arrest, tricyclic antidepressant overdose) and not as routine early cardiac arrest management.

Important Medical Disclaimer

The information on this product page is provided for general educational purposes and is intended to support — not replace — the professional judgement of qualified healthcare providers. This content has been prepared in accordance with YMYL (Your Money Your Life) standards to ensure accuracy, balance, and patient safety. All drug therapy decisions must be made by a licensed physician or pharmacist with full knowledge of the patient’s medical history, comorbidities, and concurrent medications. Self-diagnosis and self-treatment of gastrointestinal conditions using prescription medications without medical supervision can be dangerous and may result in delayed diagnosis of serious underlying conditions. If you have questions about this medication or your treatment, please consult your doctor or pharmacist.